To evaluate the near-term efficacy and safety of ultrafiltration concentration of ascites back into the abdominal cavity for improving recalcitrant bloody ascites in cirrhosis with liver cancer. Thirty-nine patients with hepatitis B cirrhosis with hepatocellular carcinoma with intractable ascites were selected, among which 21 patients with bloody ascites were treated as the treatment group, and the rest were the control group, and the ascites or bloody ascites was concentrated by extracorporeal ultrafiltration and re-infused into the peritoneal cavity. The recent clinical symptoms, abdominal circumference and urine volume of patients in both groups improved significantly after ultrafiltration of concentrated ascites back into the abdominal cavity, and there were no significant changes in heart rate, blood pressure (systolic/diastolic), hemoglobin, plasma albumin, serum creatinine and electrolytes compared with those before treatment. The treatment of recalcitrant hemorrhagic ascites in hepatocellular carcinoma by ultrafiltration and concentration of ascites back into the peritoneal cavity is safe, with reliable recent results, and is beneficial to improve the survival quality of patients with advanced hepatocellular carcinoma.